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B-cellCommonVariable ImmunodeﬁciencyDisorders (CVIDs) are themost prevalent cause of primary antibody failure.
CVIDs are highly variable and a genetic causes have been identiﬁed in b5% of patients. Here, we performedwhole
genome sequencing (WGS) of 34 CVIDpatients (94% sporadic) and combined themwith transcriptomic proﬁling
(RNA-sequencing of B cells) from three patients and three healthy controls. We identiﬁed variants in CVID dis-
ease genes TNFRSF13B, TNFRSF13C, LRBA and NLRP12 and enrichment of variants in known and novel disease
pathways. The pathways identiﬁed include B-cell receptor signalling, non-homologous end-joining, regulation
of apoptosis, T cell regulation and ICOS signalling. Our data conﬁrm the polygenic nature of CVID and suggest
individual-speciﬁc aetiologies in many cases. Together our data show that WGS in combination with RNA-
sequencing allows for a better understanding of CVIDs and the identiﬁcation of novel disease associated
pathways.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Common Variable Immunodeﬁciency Disorders (CVIDs) are the most
clinically prevalent primary antibody deﬁciencies, present in about 1 in
25,000 people [1]. CVID is characterised by recurrent infections, lowon Variable Immunodeﬁciency
ncies); GWAS, (Genome-wide
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. This is an open access article underserum levels of IgG, low IgA and/or IgM and poor speciﬁc antibody
responses [2]. CVID is currently a diagnosis of exclusion leaving a highly
heterogeneous patient group in terms of clinical features and complica-
tions. Some patients have a relatively mild phenotype, comprising of
recurrent bacterial infections and infection-related complications while
others suffer from disease related complications such as autoimmune cy-
topenias, polyclonal lymphoproliferation, enteropathy and lymphoidma-
lignancy, indicating underlying immune dysregulation [3].
The heterogeneous disease phenotype of CVID has made resolving
genetic aetiologies challenging. Causative variants of CVID-like primary
antibody failure have been described in CD19 [4–6], CD21 [7], CD81 [8],
CD20 [9], ICOS [10,11] and TNFRSF13C [12], conditions now classiﬁed as
speciﬁc deﬁciencies in these genes (Table S1). Mutations in CD27 [13,
14], PLCG2 [15,16], LRBA [17,18], NFKB2 [19,20], PIK3CD [21,22] and
NLRP12 [23] cause CVID-like symptoms often combined with a more ex-
tensive clinical phenotype (Table S1). Variants in TNFRSF13B [24–26],
TNFRSF13C [27], FCGR2A [28] andHLA [29] have been described to predis-
pose to CVID (Table S1). Together these variants only explain the genetic
cause of CVID-like diseases in very few patients and all genes were iden-
tiﬁed in familial cases of CVID,while the vastmajority of CVIDpatients are
sporadic. Thewide variety in genes implicated in CVID further underlines
the heterogenic nature of the disease. Further unravelling of thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
302 P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314underlying genetic causes of sporadic CVID would give additional insight
into the disease, opportunities for better patient stratiﬁcation and novel
insights into treatment opportunities.
In 2011 Orange et al. published the ﬁrst genome-wide association
study (GWAS) of CVID to identify genomic regions associated with
CVID development [30]. Analysis of 363 patients and 3031 controls led
to the conclusion that CVID is likely to be a polygenic disease with mul-
tiple novel susceptibility loci implicated. However, as of yet this has not
resulted in further identiﬁcation and elucidation of genes or variants
that cause or predispose for sporadic CVID emphasizing the difﬁculties
in studying this highly variable disease.
The development of next generation sequencing techniques has
transformed the identiﬁcation of the genetic basis of Mendelian dis-
eases. In contrast, identiﬁcation of the genetic basis remains challenging
in polygenic conditions. Here, we present the ﬁrst whole genome
sequencing (WGS) data for a cohort of CVID patients to investigate
novel underlying aetiologies. We further leveraged the potential of
WGS by combining the results with global transcriptomic proﬁling
through RNA-sequencing (RNA-seq). Because of the complex and prob-
able polygenic nature of CVID, we combine the identiﬁcation of genes
of interest with pathway-based analysis and focus on combining these
results to identify pathways dysregulated in CVID.Table 1
Overview of clinical information on the 34 CVID patients.
Patient no Sex Age at onset
of symptoms
CD19 counta CD3 counta CD4 counta CD8 c
Normal 0.1–0.5 0.7–2.1 0.3–1.4 0.2–0.
C003 F 54 ↓↓ ↓ Normal Norm
C006 M 34 Normal Normal Normal Norm
C018 M 8 Normal Normal Normal Norm
C019 M 18 Normal Normal Normal ↑
C023 M 25 Normal Normal Normal Norm
C024 F 48 Normal ↓ Normal ↓
C028 F 47 Normal Normal Normal Norm
C032 M 26 ↓ Normal ↓ ↓
C036 F 19 Normal Normal Normal Norm
C038 M 5 Normal Normal Normal Norm
C044 F 31 Normal Normal Normal Norm
C063 F 48 Normal Normal Normal Norm
C065 M 5 Normal Normal Normal Norm
C072 F 34 ↓↓ Normal Normal Norm
C078 M 13 Normal Normal Normal Norm
C082 F 11 ↓↓ Normal Normal Norm
C085 F 37 Normal Normal Normal Norm
C089 F 17 ↓↓ Normal Normal Norm
D038 M 22 Normal Normal Normal Norm
D209 M 41 Normal Normal Normal Norm
D232 F 44 ↑ ↑ ↑ Norm
D269 F 44 Normal ↓ ↓ Norm
D276 M 1 ↓↓↓ Normal Normal Norm
D325 F 35 Normal ↓ Normal Norm
D334 M 15 Normal Normal Normal Norm
D345 F 20 Normal ↑ Normal ↑
D374 M 3 Normal Normal Normal Norm
D575 M 2 Normal Normal Normal Norm
D641 F 20 Normal ↓ ↓ Norm
D667 M 13 Normal Normal Normal Norm
D705 F 49 Normal Normal Normal Norm
D745 M 5 Normal ↑ ↑ ↑
D765 F 30 Normal Normal Normal Norm
D839 M 25 Normal ↓ Normal Norm
↓= between lower normal and half lower normal values; ↓↓= less than half lower normal v
value;↑↑= more than twice upper normal value.
a Values at diagnosis.
b Values at diagnosis not available; values listed are post-infusion of intravenous immunogl2. Material and methods
2.1. Samples
Patientswere recruited into the study through theClinical Immunology
Department at the Oxford University Hospital, Oxford. All patients gave
informed written consent and the studies were performed according to
the Declaration of Helsinki. All 34 patients were of Caucasian origin and
met the ESID diagnostic criteria at the time of enrollment [2]. Themajority
of patients were regularly followed in the Clinical Immunology clinic at 6
monthly intervals over a period of up to 30 years with detailed clinical
information entered into the local database that enabled accurate clinical
phenotyping. A summary of the clinical phenotype and laboratory charac-
teristics of the patient cohort can be found in Table 1 and amore complete
overview can be found in Table S2.
2.2. WGS500
A cohort of 34 CVID patients was selected for WGS as part of the
WGS500project [31]. This is a collaborative project between theUniver-
sity of Oxford and Illumina, which aims to sequence the genomes of 500
individuals with a range of diseases including rare inherited diseases,ounta IgG levelsa IgM levelsa IgA levelsa Clinical phenotype3
9 6.0–16.0 0.4–2.5 0.8–3.0
al ↓↓ Normal ↓↓ Polyclonal lymphoproliferation
al ↓↓ ↓↓ ↓↓ Polyclonal lymphoproliferation
al ↓↓ ↓↓ ↓↓ No disease-related complications
↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓ No disease-related complications
↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓ Polyclonal lymphoproliferation
↓ Normal ↓↓ Polyclonal lymphoproliferation
al ↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓ No disease-related complications
al ↓ ↓↓ ↓ Polyclonal lymphoproliferation;
autoimmune cytopenias
al ↓↓ Normal ↓↓ No disease-related complications
al ↓ ↓ ↓↓ No disease-related complications
al ↓↓ ↓/↓↓ ↓↓ No disease-related complications
al ↓↓ Normal ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓b Autoimmune cytopenias
al ↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓ ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓ ↓↓ No disease-related complications
al ↓ Normal ↓↓ No disease-related complications
al ↓↓ Normal ↓↓ Polyclonal lymphoproliferation;
autoimmune cytopenias
al ↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓ ↓↓ Polyclonal lymphoproliferation;
autoimmune cytopenias
al ↓↓ ↓ ↓↓ No disease-related complications
↓↓ ↓ ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓↓ ↓↓ No disease-related complications
al ↓↓ ↓/↓↓ ↓↓ No disease-related complications
al ↓↓ ↓ ↓↓ No disease-related complications
al ↓/↓↓ ↓/↓↓ Normal/↓ No disease-related complications
↓↓ Normal ↓↓ No disease-related complications
al ↓↓ Normal ↓↓ No disease-related complications
al ↓↓ ↓ ↓↓ Polyclonal lymphoproliferation
alue; ↓↓↓= undetectable; ↑= between upper normal value and twice upper normal
obulin, which does not alter IgA levels.
Table 2
Additional details on variants highlighted in the text.
Chromosome:
position
Gene
symbol
Transcript variant Protein variant dbSNP ID Case samples
with variant
(freq)
1000
Genomes
frequency
No.
WGS500
(freq)
SIFT
function
prediction
SIFT
score
PolyPhen-2
function
prediction
Conservation
phyloP
p-value
Samples
Described variants
17:16842991 TNFRSF13B c.752CNT p.P251L 34562254 7 (20.59) 18.07 47.0 (19.67) Tolerated 0.69 Benign C006, C028, C038, C072,
D667, D705, D745
17:16843084 TNFRSF13B c.659TNC p.V220A 56063729 1 (2.94) 1.03 10.0 (4.18) Tolerated 0.86 Benign D269 (hom)
17:16843666 TNFRSF13B c.605GNA p.R202H 104894649 1 (2.94) 2.0 (0.84) Damaging 0.02 Benign D38
17:16852187 TNFRSF13B c.310TNC p.C104R 34557412 1 (2.94) 0.32 5.0 (2.09) Damaging 0 Probably
damaging
2.90E+00 D38
17:16852282 TNFRSF13B c.215GNA p.R72H 55916807 1 (2.94) 0.32 3.0 (1.26) Tolerated 0.29 Benign C003
19:54314003 NLRP12 c.910CNT p.H304Y 141245482 1 (2.94) 0.27 1.0 (0.42) Damaging 0.04 Probably
damaging
C065
22: 42322716 TNFRSF13C c.62CNG p.P21R 77874543 2 (5.88) 5.59 22.0 (9.21) Tolerated 0.64 Benign C038, C089 (Hom)
GWAS
6:30671229 MDC1 c.5648GNA p.R1883Q 28994875 2 (5.88) 1.14 5 (2.09) Damaging 0.03 Probably
damaging
5.25E−04 C023, C078
6:30671726 MDC1 c.5234CNG p.P1745R 28994871 5 (14.71) 1.37 9 (3.77) Damaging 0.04 Probably
damaging
C006, C024, D269
(hom),
D667, D745
6:30673064 MDC1 c.3896GNA p.R1299Q 144657716 5 (14.71) 3.60 9 (3.77) Activating 1 Benign C006, C024, D269
(hom),
D667, D745
6:30673625 MDC1 c.3335CNT p.S1112F 28987085 5 (14.71) 1.37 9 (3.77) Damaging 0.01 Possibly damaging C006, C024, D269
(hom),
D667, D745
6:31598523 PRRC2A c.2410CNT p.R804C 11538262 1 (2.94) 0.74 7 (2.93) Probably
damaging
3.89E−03 C089
6:31599916 PRRC2A c.3466CNT p.R1156W 200579772 1 (2.94) Probably
damaging
6.38E−04 C036
6:31600639 PRRC2A c.4189CNT p.R1397W 201074309 1 (2.94) Probably
damaging
3.05E−03 D209
6:31605016 PRRC2A c.6248TNC p.F2083S 35595439 3 (8.82) 0.51 7 (2.93) Possibly damaging 8.13E−04 C006, C024, D269 (hom)
6:31929737 SKIV2L c.970CNT p.R324W 36038685 1 (2.94) 1.10 4 (1.67) Damaging 0.01 Possibly damaging D641
6:31931903 SKIV2L c.1860+1_1860+10delGTGCGTCTGT 1 (2.94) 5.46E−06 C044
PID genes
2:220022915 NHEJ1 c.170GNA p.R57Q 61753339 1 (2.94) 1.0 (0.42) Damaging 0 Probably
damaging
4.54E−02 D325
4:151392815* LRBA c.6661TNC; c.6628TNC p.S2221P; p.S2210P 1 (2.94) Damaging 0 Probably
damaging
7.35E−04 D374
6:32803458 TAP2 c.701TNA p.L234Q 138708621 1 (2.94) Damaging 0.02 Probably
damaging
D641
7:6045634 PMS2 c.52ANG p.I18V 63750123 2 (5.88) 0.43 9.0 (3.77) Damaging 0 Probably
damaging
8.00E−03 C085, D374
8:42176165 IKBKB c.1330CNT; c.1336CNT; c.1159CNT p.R444W; p.R387W;
p.R446W
202136671 1 (2.94) Damaging 0.01 Possibly damaging 7.91E−01 D345
8:48691175 PRKDC c.11698CNG; c.11605CNG p.L3869V; p.L3900V 201214138 1 (2.94) Probably
damaging
3.27E+00 C024
8:48775035* PRKDC c.5818TNC p.Y1940H 1 (2.94) Probably
damaging
1.31E−02 D232
10:14965056 DCLRE1C c.640TNA; c.985TNA; c.625TNA p.L214M; p.L329M;
p.L209M
41299658 1 (2.94) 0.05 1.0 (0.42) Damaging 0.01 Probably
damaging
D334
11:4108092 STIM1 c.1859+1GNA; c.1541+319GNA 118128831 4 (11.76) 0.51 9.0 (3.77) 3.91E−03 C024, C044, D232, D269
11:36614561 RAG2 c.1158CNA p.F386L 34629171 2 (5.88) 0.37 8.0 (3.35) Damaging 0.02 Probably
damaging
C019, C023
11:94178974* MRE11A c.1783+1411TNC; c.1867+2TNC 1 (2.94) 9.66E−01 C006
11:108143456 ATM c.3161CNG p.P1054R 1800057 1 (2.94) 1.51 11.0 (4.6) Damaging 0.01 Probably
damaging
1.33E−02 C082
(continued on next page)
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Table 2 (continued)
Chromosome:
position
Gene
symbol
Transcript variant Protein variant dbSNP ID Case samples
with variant
(freq)
1000
Genomes
frequency
No.
WGS500
(freq)
SIFT
function
prediction
SIFT
score
PolyPhen-2
function
prediction
Conservation
phyloP
p-value
Samples
12:25368405 KRAS c.451-5560TNA; c.540TNA p.C180* 373169526 1 (2.94) 8.51E+00 C089
12:133252342* POLE c.1085ANG p.Y362C 1 (2.94) Damaging 0 Probably
damaging
7.41E−03 D839
16:27414502 IL21R c.11GNA; c.−17+563GNA p.R4H 117535117 2 (5.88) 0.65 4.0 (1.67) Damaging 0 C028, D38
16:27460561 IL21R-AS1;
IL21R
c.1574TNA; c.1640TNA p.V525D; p.V547D 200674281 1 (2.94) Damaging 0.04 Possibly damaging D345
19:1627422 TCF3 c.302ANG p.K101R 41275842 1 (2.94) 0.63 2.0 (0.84) Damaging 0.01 Possibly damaging 5.18E+00 D374
19:42383644 CD79A c.305CNA; c.419CNA p.T102N; p.T140N 148797987 2 (5.88) 0.31 1.0 (0.42) Damaging 0.02 Probably
damaging
3.30E+00 C089, D575
19:55494283 NLRP2 c.1151CNG; c.1148CNG; c.1217CNG p.T383R; p.T406R; p.T384R 139903547 3 (8.82) 0.34 2.0 (0.84) Damaging 0.01 Probably
damaging
3.52E−01 C024, C038, D38
X:100609671* BTK c.1049dupA; c.1577dupA; c.1679dupA p.N350fs*11; p.N526fs*11;
p.N560fs*11
1 (2.94) D276 (hemi)
X:100611132* BTK c.1474CNT; c.1039-1450CNT; c.1576CNT p.R492C; p.R526C 1 (2.94) Damaging 0.05 Possibly damaging C063
X:154005089* DKC1 c.1495_1497delAAG;
c.*718_*720delAAG;
c.1510_1512delAAG
p.K505del; p.K500del 1 (2.94) 2.0 (0.84) C019 (hemi)
Most common variants
19:54756246 LILRB5 c.1556TNC; c.1259TNC; c.1559TNC p.I420T; p.I519T; p.I520T 117421142 6 (19.35) 0.87 9 (3.77) Activating 1 Benign C003, C023, C038, D38,
D334, D705
1 hop genes
1:161599778 FCGR3B c.214GNA; c.217GNA; c.109GNA; c.58GNA p.V73M; p.V37M; p.V72M;
p.V20M
375357751 1 (3.23) 0 Damaging 0 Probably
damaging
C089
2:111923737 BCL2L11 c.*2124CNT; c.*2139CNT; c.*2014CNT;
c.*2151CNT; c.*1929CNT; c.*2141CNT;
c.*2195CNT; c.*2144CNT
144847549 1 (3.23) 0.61 (0) 9.10E−03 C032
2:234113242 INPP5D c.3443CNG; c.3446CNG p.A1149G; p.A1148G 375825105 1 (3.23) 0 Possibly damaging 2.90E−04 C065
4:2834080 SH3BP2 c.1513CNT; c.1600CNT; c.1429CNT p.R534W; p.R477W;
p.R505W
148761331 1 (3.23) 0.28 3 (1.26) Damaging 0.01 Possibly damaging C078
4:102751014 BANK1 c.120GNC; c.30GNC; c.71-25178GNC p.W40C; p.W10C 35978636 2 (6.45) 0.55 8 (3.35) Damaging 0 Probably
damaging
4.55E−05 C032, C082
5:134086744 CAMLG c.*104CNA 11552196 3 (9.68) 0.8 5 (2.09) D374, D575, D705
5:150422217* TNIP1 c.1018CNG; c.859CNG p.Q287E; p.Q340E 1 (3.23) 0 Damaging 0.05 Probably
damaging
3.30E−06 D38
5:150441774* TNIP1 c.113-1GNT; c.272-1GNT 1 (3.23) 0 1.05E−03 D667
5:158124754* EBF1 c.*1364_*1365insT 1 (3.23) 1 (0.42) 1.68E−06 C032
6:32823948 PSMB9 c.94GNA p.V32I 241419 1 (3.23) 2.19 10 (4.18) Damaging 0 7.98E−06 D209
6:32826267 PSMB9 c.517CNT p.R173C 17213861 2 (6.45) 0.14 4 (1.67) Damaging 0.01 C024, C036
6:138198245 TNFAIP3 c.838CNT p.R280W 150198888 1 (3.23) 0.04 0 Damaging 0 Possibly damaging C023
8:11418861* BLK c.1080CNA p.D360E 1 (3.23) 0 Damaging 0 Possibly damaging 2.13E−04 C003
11:77937972 GAB2 c.746ANG; c.632ANG p.Y249C; p.Y211C 146509778 1 (3.23) 1 (0.42) Damaging 0.03 Possibly damaging 1.69E−05 C038
19:932497* ARID3A c.460_462delGAG p.E154del 1 (3.23) 0 C072
The complete results of the different analyses can be found in Tables S3–S7. Variants are heterozygous unless the sample number is followed by (hom)which indicates a homozygous variant or (hemi) in which case the variant is hemizygous. Novel
variants are marked with *. No. patients WGS500 indicates the number of patients in the WGS500 cohort (excluding CVID) with the variant. All variants have been conﬁrmed in IGV.
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the variant in the non-cancer, non-CVID samples of theWGS500 project
(n = 239) is listed in Table 2 and Tables S3–S7 and S15.
2.3. Whole genome sequencing
Genomic DNA was extracted from peripheral blood mononuclear
cells (PBMCs) using the FlexiGene DNA kit (Qiagen) according to the
manufacturer's instructions. The DNA was quantiﬁed by ﬂuorescence
using the Quibit Fluorometer (Invitrogen) and the quality assessed by
running b500 ng on a 1% TAE agarose gel for 1 h at 70 V.Whole genome
sequencing was performed on 3.5–7.5 ng DNA on either the Illumina
HiSeq2000 or the HiSeq2500 run in standard mode using v2.5 or v3 se-
quencing chemistry (Core Genomics, WTCHG). Brieﬂy, the genomic
DNA was fragmented, end-paired, A-tailed and adapter-ligated before
size selection and ampliﬁcation for a multiplexed library preparation.
The libraries were then paired end sequenced and sequenced to an av-
erage coverage between 27 and 40 quality reads per base (100 base pair
reads).
2.4. Mapping and variant calling
Reads were mapped to the GRCh37d5/hg19 human reference se-
quence using Stampy and the SNVs and short InDels were called with
Platypus www.well.ox.ac.uk/platypus (Core Bioinformatics, WTCHG)
[32].
2.5. Variant ﬁltering
The created vcf ﬁles were analysed using QIAGEN's Ingenuity® Var-
iant Analysis™ (IVA) software (www.qiagen.com/Ingenuity, QIAGEN
Redwood City). For all analysis a conﬁdence ﬁlter was applied to
exclude poor quality calls (Table 3) [33]. Frequency (1000 Genomes
and WGS500) and predicted deleterious ﬁlters (SIFT and PolyPhen)
were applied to prioritise high quality calls for non-synonymous and
likely pathogenic variants (Table 3). IVA allowed the use of custom
gene lists (Notes S1 and S3) as biological ﬁlters with options for
‘1 hop’ analysis both up and downstream of these genes [34]. The
‘1 hop’ function identiﬁes interactions between genes from literature.
Here, this function was used to create the list of variants in the genes
interacting with described CVID genes.
Genomic regions described in GWAS were transferred from hg18
into hg19 using http://www.genome.ucsc.edu/cgi-bin/hgLiftOver.
WGS variants were ﬁltered as described in Table 3 and restricted to
those in the identiﬁed genomic regions [30].
All variants reported (except the results of the pathway analysis)
were manually inspected using the Integrative Genome Viewer (IGV)
[35]. Heterozygous variants were included if the variant was present
in N25% of all reads with N15% in both forward and reverse reads.
Homozygous variants were included if present in N80% of all reads
and a minimum of 60% of reads in both directions. Variants found in
regions with a high density of insertions/deletions were excluded to
reduce false positive calls resulting from mapping errors.
2.6. Sanger sequencing
Primerswere designed using primer3 software (http://bioinfo.ut.ee/
primer3/) (Table S14). 25 ng DNAwas ampliﬁed using a 25 μl PCR reac-
tion containing 2.5 μl 10× Buffer, 1.5 mMMgCl2, 0.2 mMdNTP, 250 nM
primer (each direction) and 0.5 U Platinum Taq DNA polymerase
(Invitrogen). Cycling conditions were an initial denaturation step at
94 °C for 2–5 min followed by 30 cycles of 94 °C for 30 s, 56–63 °C
(Table S14) for 30 s and 72 °C for 40 s followed by a ﬁnal elongation
step of 5 min at 72 °C. The PCR product was cleaned using either a
QIAquick PCR puriﬁcation kit (Qiagen) or by incubating 0.1 μl ExoI and
0.1 μl CIP with 0.4 μl NEB buffer 3 in an 8 μl reaction at 37 °C for30min before inactivation at 95 °C for 5min. 3.5 μl cleaned-up template
DNA was sequenced using the Big Dye Terminator 3.1 according to the
manufacturer's instructions (Applied Biosystems).
2.7. RNA-sequencing
RNA-seq data were generated for enriched B cells from three CVID
patients and three healthy controls. PBMCs were isolated using
Lymphoprep (Stemcell Technologies) and B-cells were enriched using
CD19 microbeads (Miltenyi Biotec) according to the manufacturer's in-
structions. After isolation, purity of the B-cells was 61.9–96.1% as
determined by FACS analysis. RNA was extracted using a RNeasy Mini
Kit (Qiagen) following themanufacturer's instructions. Spectrophotom-
etry (Nanodrop 2000; Thermo Scientiﬁc) was used to quantitate the RNA
yield and the quality was determined by on-chip electrophoresis (Biorad
Bioanalyzer; Agilent). RNA-seq was performed on 600–1000 ng RNA
on the Illumina HiSeq2500 run in standard mode using v1 sequencing
chemistry (Core Genomics, WTCHG). Brieﬂy, the mRNA fraction was
selected from the total RNA before conversion to cDNA. dUTP was
incorporated from the second strand cDNA synthesis. The cDNA was
end-repaired, A-tailed and adapter-ligated. Prior to ampliﬁcation the
samples underwent uridine digestion. The prepared libraries were size
selected, multiplexed and QC'ed before paired end sequencing over
one lane of a ﬂow cell. Data were aligned to the reference and
reads mapped to genes using HTSeq (Core Bioinformatics, WTCHG)
[36]. QC to determine the proportion of reads mapping to genes
and variation within the dataset was carried out using R (R Core
Team, 2012; http://www.R-project.org) (see Fig. S4). The genes with
mapped reads were ﬁltered so only those with at least 10 reads in at
least three samples were retained prior to normalisation. This resulted
in a reduction from 32,426 to 16,546 transcripts. The data were normal-
ised using the TMM method and the edgeR R package [37]. Biological
pathway enrichment was generated through the use of QIAGEN'S Inge-
nuity Pathway Analysis (IPA®, www.qiagen.com/ingenuity, QIAGEN
Redwood City).
2.8. Protein structural analysis
Variants were mapped to corresponding protein structures in Pro-
teinData Bank (PDB) (LRBA, Protein Data Bank (PDB) ID 1T77; TNFAIP3,
PDB ID 3ZJE; SH3BP2, PDB ID 2CR4) (http://www.rcsb.org/) [38]. The
structureswere analysed using PyMOL (The PyMOLMolecular Graphics
System, Version 1.5.0.4 Schrödinger, LLC; http://pymol.org/). The effect
of a variant on protein stability was assessed using mCSM [39].
3. Results
3.1. Whole genome-sequencing and CVID
As part of the WGS500 project aiming to sequence the genomes of
500 individuals with a range of diseases, we performed WGS for a co-
hort of 32 sporadic CVID patients and one grandmother–grandson pair
[31]. The cohort had an equal sex distribution and the median age of
disease onset was 23.5 years. All patients met the European Society for
Immunodeﬁciencies (ESID) diagnostic criteria for CVIDs [2].We exclud-
ed patients with lymphomas, though patient C003 developed a B cell
lymphoma four years into the study. Information on the clinical pheno-
types and immunotypes of the patients can be found in Table 1 and
Table S2. WGS using the Illumina platform with an average coverage
between 27 and 40 quality reads per base identiﬁed 14,819,871 variants
(single nucleotide variants (SNVs) and short InDels) across the 34
patients. Initial analysis conﬁrmed a familial relationship between the
grandmother (D232) and grandson (C018) pair and revealed long
runs of homozygosity in one of the sporadic patients (D269).
To validate our data we ﬁrst looked for variants previously described
to cause or predispose for CVID-like diseases in our patients (variants are
Ta
bl
e
3
O
ve
rv
ie
w
of
ba
si
c
ﬁl
te
ri
ng
ap
pl
ie
d
in
th
e
m
aj
or
it
y
of
th
e
an
al
ys
es
.
Fi
lt
er
Th
re
sh
ol
ds
Ra
ti
on
al
e
N
um
be
r
of
va
ri
an
ts
in
34
pa
ti
en
ts
(n
um
be
r
of
ge
ne
s)
N
um
be
r
of
va
ri
an
ts
in
31
pa
ti
en
ts
(n
um
be
r
of
ge
ne
s)
14
,8
19
,8
71
(2
0,
89
1)
14
,4
57
,8
84
(2
0,
62
7)
Co
nﬁ
de
nc
e
Ca
ll
qu
al
it
y
is
at
le
as
t
20
in
an
y
sa
m
pl
e
V
ar
ia
nt
pa
ss
ed
up
st
re
am
pi
pe
lin
e
ﬁl
te
ri
ng
Re
ad
de
pt
h
is
at
le
as
t
10
in
an
y
sa
m
pl
e
V
ar
ia
nt
is
ou
ts
id
e
to
p
0.
2%
m
os
t
ex
on
ic
al
ly
va
ri
ab
le
10
0
ba
se
w
in
do
w
s
in
he
al
th
y
pu
bl
ic
ge
no
m
es
Ex
cl
ud
e
po
or
qu
al
it
y
va
ri
an
t
ca
lls
11
,3
04
,1
76
(2
0,
59
4)
11
,0
38
,0
08
(2
0,
57
7)
N
o.
re
ve
rs
e
re
ad
s
≥
1
re
ad
s
co
nt
ai
ni
ng
va
ri
an
t
Re
du
ce
st
ra
nd
bi
as
11
,1
18
,9
02
(2
0,
58
3)
10
,8
59
,6
16
(2
0,
56
4)
N
o.
fo
rw
ar
d
re
ad
s
≥
1
re
ad
s
co
nt
ai
ni
ng
va
ri
an
t
Re
du
ce
st
ra
nd
bi
as
10
,9
40
,1
42
(2
0,
57
1)
10
,6
87
,7
81
(2
0,
55
4)
Co
m
m
on
va
ri
an
ts
V
ar
ia
nt
ha
s
an
al
le
le
fr
eq
ue
nc
y
le
ss
th
an
5%
in
10
00
G
en
om
es
Pr
oj
ec
t
Ex
cl
ud
e
co
m
m
on
va
ri
an
ts
4,
80
8,
17
6
(2
0,
13
2)
4,
58
2,
53
2
(2
0,
08
0)
W
G
S5
00
M
A
F
V
ar
ia
nt
ha
s
an
al
le
le
fr
eq
ue
nc
y
le
ss
th
an
5%
in
no
n-
CV
ID
,n
on
-c
an
ce
r
W
G
S5
00
sa
m
pl
es
Ex
cl
ud
e
te
ch
ni
ca
la
rt
ef
ac
ts
2,
72
1,
01
4
(1
9,
67
8)
2,
53
7,
26
3
(1
9,
58
4)
Pr
ed
ic
te
d
de
le
te
ri
ou
s
Pa
th
og
en
ic
/l
ik
el
y
pa
th
og
en
ic
or
as
so
ci
at
ed
w
it
h
an
y
ty
pe
of
ga
in
of
fu
nc
ti
on
or
as
so
ci
at
ed
w
it
h
lo
ss
of
fu
nc
ti
on
(f
ra
m
es
hi
ft
,i
ns
er
ti
on
s/
de
le
ti
on
s,
ch
an
ge
s
in
st
ar
t
of
st
op
co
do
n,
m
is
se
ns
e
m
ut
at
io
ns
w
hi
ch
ar
e
pr
ed
ic
te
d
to
no
t
be
to
le
ra
te
d
by
SI
FT
or
Po
ly
Ph
en
,s
pl
ic
e
si
te
lo
ss
up
to
2
bp
in
to
th
e
in
tr
on
,d
el
et
er
io
us
to
a
m
ic
ro
RN
A
or
va
ri
an
ts
le
ad
in
g
to
a
st
ru
ct
ur
al
va
ri
an
ts
)
Ex
cl
ud
e
va
ri
an
ts
w
hi
ch
ar
e
un
lik
el
y
to
ha
ve
ef
fe
ct
on
ge
ne
fu
nc
ti
on
47
68
(3
73
7)
44
22
(3
52
4)
D
et
ai
ls
on
th
e
se
tt
in
gs
us
ed
an
d
th
e
ra
ti
on
al
e
be
hi
nd
us
in
g
th
es
e
ﬁl
te
rs
an
d
th
e
nu
m
be
r
of
va
ri
an
ts
le
ft
af
te
r
ﬁl
te
ri
ng
in
ei
th
er
31
or
34
pa
ti
en
ts
ar
e
in
di
ca
te
d.
306 P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314listed in Table S1, results are summarised in Table S3). This analysis re-
vealed ﬁve previously reported variants in TNFRSF13B, tumour necrosis
factor receptor superfamilymember 13B (also known as TACI).We iden-
tiﬁed one patient heterozygous for p.C104R, previously reported to abol-
ish ligand binding in the heterozygous state through haploinsufﬁciency
[24,26,40]. Other TNFRSF13B variants (p.P251L, p.V220A, p.R202H and
p.R72H) have originally been linked to CVID, but a later study found
equal frequencies in CVID patients and healthy controls as we found
here (as compared to the frequency in the 1000 genomes project and
the non-CVID WGS500 samples) [24–26,41]. Our analysis also identiﬁed
one patient heterozygous for the p.H304Y variant in the inﬂammatory
modulator gene NLRP12 [23]. We identiﬁed two patients with the
p.P21R variant (one homozygous) in tumour necrosis factor receptor su-
perfamily member 13C gene TNFRSF13C (BAFFR) [27] which is reported
to have functional consequences through effects on multimerisation
[42]. We noted poor coverage of TNFRSF13C in our WGS data and subse-
quent Sanger sequencing of all 34 patients revealed an additional 4
patients heterozygous for this variant (frequency of 0.176 compared to
0.059 in the 1000 Genomes Project) [41]. Details of variants highlighted
throughout this report can be found in Table 2.
To identify novel variants of interest we selected high quality, and
likely pathogenic variants. Because of the expected polygenic nature of
CVID we used the relatively mild selection criteria (1000 Genomes
and WGS500 frequency b0.05 and classiﬁed as pathogenic or likely
pathogenic by Ingenuity Variant Analysis (IVA)), and included both het-
erozygous and homozygous variants resulting in 4768 variants in 3737
genes (details on the ﬁltering can be found in Table 3). The majority of
variants were SNVs (Fig. 1a) in exonic regions together with a number
in annotated regulatory regions including promoters, 5′ and 3′UTRs,
microRNA binding sites, splice sites and noncoding RNAs (Fig. 1b). In
our analysis strategy (Fig. 1c) we focused on variants present in regions
implicated inGWAS [30], genes involved in described primary immuno-
deﬁciency disorders (PIDs) or genes with a direct link with previously
identiﬁed CVID genes. Moreover, we also looked at pathways in which
variants were overrepresented.
3.2. GWAS and PID genes
The CVID GWAS conducted by Orange and colleagues [30] included
29 of the patients described here. Within the regions associated with
CVID developmentwe identiﬁed 43 potentially pathogenic rare variants
(Table S4) of which 39 are located in the HLA region of chromosome 6.
We highlight the variants of interest based on a combination of gene
function, frequency (1000 Genomes Project and WGS500 compared to
our cohort) and predicted deleteriousness (PolyPhen, SIFT and muta-
tion taster prediction score) (Table 2) [41,43–45]. Two variants were
identiﬁed in SKIV2L, a gene associated with trichohepatoenteric syn-
drome 2 and syndromic diarrhoea, two rare diseases associated with
low immunoglobulin levels and the absence of vaccine responses [46].
Four variants (p.R1883Q, p.P1745R, p.R1299Q, p.S1112F) were ob-
served in MDC1, a gene involved in DNA damage response [47]. We
also identiﬁed six patients (17.6%) with predicted deleterious variants
in PRRC2A (p.R804C, p.R1556W, p.R1397W, p.F2083S) a gene associated
with type 1 diabetes and rheumatoid arthritis, suggesting a function in
immune regulation [48,49]. We did not ﬁnd any predicted deleterious
variants in CLEC16A, a gene recently associated with CVID via GWAS
[50].
Next, we hypothesised that a combination of heterozygous variants
in geneswhere homozygous variants cause PIDs (Note S1)may contrib-
ute to the pathogenicity of CVID as previously described for rheumatoid
arthritis [51]. Analysis resolved 55 variants in described PID genes
(Table S5). Again the most likely disease causing variants were identi-
ﬁed based on frequency, gene function and predicted deleteriousness
(Table 2). Variants of interest include a novel, predicted damaging
p.S2221P/p.S2210P variant in LRBA and heterozygous predicted delete-
rious variants in other genes in which loss of function leads to low or
a b
c
Fig. 1.Overviewof analysis strategy and distribution of variant type and genetic location of variants. (a) Distribution of variant type for variants that passed the ﬁltering steps as described
in Table 3. (b)Number of variants in different genetic locations in the 4768 variants that passed the basicﬁltering described in Table 3. (c)Overviewof the analysis strategies applied to the
WGS data.
307P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314absent immunoglobulin levels (IKBKB), combinedwith low or absent B-
cell subtypes (TCF3, BTK, CD79A, PMS2, POLE), and/or T-cell dysregula-
tion (IL21R, STIM1, TAP2, DKC1) [52].
We identiﬁedﬁve CVIDpatientswith heterozygous variants in genes
which are involved in non-homologous end joining (NHEJ) or V(D)J
recombination and associated with T–B-SCID (DCLRE1C, PRKDC, RAG2)
[52,53]. We found an additional four variants in other PID genes in-
volved in NHEJ (NHEJ1, MRE11A, ATM, NLRP2) [53]. We also identiﬁed
variants in PID genes involved in B-cell receptor (BCR) signalling
(IKBKB, CD79a, BTK, KRAS) including a novel hemizygous variant in
BTK (p.N350fs11/p.N526fs11/p.N560fs11) that leads to a frameshift
and a premature stop codon. This male patient was previously screened
for known BTKmutations and clinically ﬁts the phenotype of X-linked
agammaglobulinaemia (XLA) caused by BTK deﬁciency [52]. Functional
follow-up is currently being conducted on this ﬁnding.3.3. Genes in sporadic CVID
Next, we further investigated the 31 sporadic CVID patients in our co-
hort (excluding the grandmother:grandson pair (Note S2) and the possi-
ble XLA patient). Filtering as described in Table 3 identiﬁed 4422 variants
of which 12 were present in ﬁve or more patients (Table S6). Of special
interest is a likely gain of function variant in LILRB5, an inhibitorymember
of the leukocyte Ig-like receptor (LIR) family, of which little is known
though other members of this protein family inhibit the activation of im-
mune cells (Table 2) [54].Likely pathogenic variants in genes for which there is evidence from
the literature of direct interaction with genes involved in CVID-like anti-
body failure were investigated using the ‘1 hop’ function in IVA (Note
S3). We identiﬁed 112 variants (Table S7) of which 38 were novel,
including predicted damaging variants in PSMB9, a gene involved in the
production of peptides for MHC class I presentation, and TNFAIP3which
plays a role in TNFα induced apoptosis and at the protein level is
known to interact with TNIP1 in which we identiﬁed two different
novel variants [55]. In addition we found variants in seven genes
involved in B-cell receptor signalling (ARID3A, INPP5D, SH3BP2, BANK1,
BLK, and GAB2), a variant in CAMLG encoding a protein involved in both
TACI and TCR signalling, and a variant in FCGR3B encoding FCγR3B
[56–62]. One patient (C032) was found to have a variant in the 3′UTR
regions of two genes (BCL2L11 and EBF1) involved in IL7Rα signalling
[63,64]. Dysregulation of this pathway leads to low T-cell numbers and
low antibody production [52]. Moreover, EBF1 is a master regulator of
early B-cell development in the bone marrow [63,65].
Overall, our analysis strategy to identify variants associatedwith CVID,
variants in GWAS regions, PID genes, themost common variants and var-
iants in genes interacting with described CVID genes (Fig. 1c), identiﬁed
on average 9.4 variants (range 5–15) in each of the 31 sporadic CVID pa-
tients. Two patients do not share any variants with the other patients,
while in others, the majority (up to 87%) of variants are also found in
one or more other patients (Fig. S1 and S2). A maximum of ﬁve variants
are shared between two patients. Fig. 2 shows the overlap of variant-
containing genes betweenpatients. Visualising this shows that all patients
share at least one variant-containing gene with another patient (Fig. 3).
Fig. 2. Distribution of variant-containing genes between patients. The number of variant-containing genes from Tables S3–S7 shared between patients.
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(IgM+/− and complex vs infections only phenotypes) (Fig S3). We did
not have sufﬁcient power to do a comparison analysis between different
patient groups.
3.4. Integration with RNA sequencing analysis
As a pilot study, RNA-seq data were generated for B-cell enriched
samples from three sporadic CVID patients (C078, C085 and C044, se-
lected on B-cell numbers and sample availability) and three healthy
controls (Figs. 4a–b; Fig. S4).We performeddifferential gene expression
analysis between CVID patients and healthy controls for 16,546 tran-
scripts revealing 262 transcripts that were differentially expressed
(false discovery rate b0.05 and fold change N2) (Fig. 4c; Table S8).
Down-regulated genes included those encoding immunoglobulin
heavy and light chains as would be expected. This, together with our
ability to reproduce a previous study showing increased FAS (amember
of the TNF receptor superfamily encoding a receptor inducing pro-
grammed cell death) expression in CVID patients suggests that this
small pilot study is able to pick up important differences in gene expres-
sion (Fig. 4d) [66]. We also ﬁnd signiﬁcantly increased expression of
four additional PID-associated genes in the CVID patients (Fig. 4d and
Fig. S) including IL10RA, encoding the receptor for interleukin 10 that
mediates immunosuppressive signals. None of the genes located in re-
gions implicated by GWAS or genes highlighted in previous paragraphs
(Table 2) were signiﬁcantly differentially expressed.
The WGS analysis we performed enables the prediction of variants
deleterious to protein function. Combining WGS with RNA-seq allowed
us to identify non-coding variants with evidence of altered gene expres-
sion. For each of the three patients with RNA-seq data, we applied ﬁlters
to their WGS data as described in Table 3, with an alteration to the pre-
dicted deleterious ﬁlter to include variants which modify promoter and
enhancer regions in addition to those with predicted deleterious effects
to protein function. To determine gain of function variants we identiﬁedvariants linked to genes with higher expression in CVID patients com-
pared to healthy controls (fold change N2 from median expression)
(n = 106, chi squared p value b 0.0001, Table S9). Fig. S6 shows the in-
creased expression of ITGB2, a described PID gene, and ICAM1, which in-
teracts with three CVID related genes (NLRP12, CD81, PLCG2). We also
identiﬁed variants linked to reduced gene expression (n = 116, chi
squared p value b 0.0001, Table S10). These include SH3BP2which inter-
actswith and activates other CVID and PID genes and VPREB3which is in-
volved in B-cell development (Fig. S6) [67,68]. No variants linked to
altered gene expression are found in the regions associated with CVID
identiﬁed by GWAS [30].3.5. Pathway analysis using WGS and RNA-seq
Due to the heterogeneous and probable polygenic nature of CVIDwe
hypothesised that different variants or combinations of variants in the
same pathway could lead to similar clinical phenotypes. Therefore we
focused on the identiﬁcation of pathways that are possibly dysregulated
in CVID. We identiﬁed the 100 pathways most enriched for genes with
predicted deleterious variants in the 31 sporadic CVID patients based
on WGS data (Table S11) and compared this with the 52 pathways
enriched for differentially expressed genes in the three CVID patients
compared to healthy controls from Ingenuity Pathway Analysis (IPA)
(Table S12). We found that 24 of these pathways overlap (Table 4),
which is signiﬁcantly greater than expected by chance (Fisher's exact
test p b 0.0001; Fig. 4e). The presence of ‘iCOS–iCOSL signalling’ in
both analyses conﬁrms previous ﬁndings [10,11]. Other pathways of in-
terest include those involved in the development of the immune system
(‘haematopoiesis from pluripotent stem cells’) and regulation of apo-
ptosis (‘death receptor signalling’); and also pathways involved in cyto-
kine signalling (‘IL-6 signalling’, ‘IL-10 signalling’) and differentiation or
signalling of T helper cells (‘CD28 signalling’, ‘PKCθ signalling’ and ‘T
helper cell differentiation’).
309P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314CVID may result from dysregulation of different pathways in differ-
ent patients and analysing all 31 patients as a group may not reveal
this. Therefore we repeated the WGS pathway analysis on a patient byFig. 3. Visualisation of the overlap of variant containing genes between patients. The distribu
(big nodes).patient basis to identify potentially important pathways at the individ-
ual level. This revealed an average of 5.8 (range 1–18) signiﬁcantly
enriched pathways per patient (Table S13). Pathways of particulartion of variant-containing genes (small nodes) listed in Tables S3–S7 between patients
a b
c
e
d
Fig. 4.Overviewof differentially expressed genes and overlap of pathway analysis ofWGS and RNA-seq data. (a) Overviewof the analysis strategy applied to the RNA-seq data. QC, quality
control; Diff. Expr., differentially expressed; HC, healthy controls. (b) The ﬁrst two principal components are plotted with the proportion of variance explained by each component (based
on reads which map to genes). (c) Volcano plot of differentially expressed genes. The signiﬁcance of differential expression between CVID patients and healthy controls is plotted against
fold change. Each point represents a single gene. Red points highlight genes with an adjusted p value b 0.05 and fold change N2. A positive fold change indicates upregulation in the CVID
patients. Some of the most differentially expressed genes are named. (d) Differential expression of FAS and IL10RA between CVID patients and healthy controls. (e) The 100 most signif-
icantly enriched pathways forWGS predicted deleterious variants were reported by IVA. Fifty-two pathways were enriched for differentially expressed genes from the RNA-seq analysis.
The overlap of enriched pathways between these two datasets is greater than expected by chance (Fisher's exact test p value b 0.0001).
310 P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314interest include ‘PI3K/AKT signalling’ (three patients) and ‘the role of
BRCA1 in DNA damage response’ (three patients) ‘Actin Cytoskeleton
signalling’ (two patients) and ‘DNA Double-strand Break repair by
non-homologous end joining’ (one patient).
3.6. Structural perspective on predicted deleterious variants
To further understand the mechanism by which the predicted
deleterious variants (Table 2) could modulate protein structure and
function, we mapped them onto available structures. Three selected
variants highlighting changes of protein surface properties and interac-
tions between secondary structure elements (helices) are shown in
Fig. 5. Changes of protein surface properties could alter protein–protein
interactionswhereas disruption of bondingwithin the proteinmay alter
folding, conformation and thus function. All three variants weremapped onto available crystal or solution NMR structures [69,70]. The
novel variant p.S2210P that we identiﬁed in LRBA was found to affect
an evolutionarily conserved, partially buried Ser2210 of LRBA located
within the BEACH domain that is crucial for protein function [69]. The
side chain of Ser2210 makes multiple hydrogen bonds with Glu2213
and Arg2397 (Fig. 5a). The Ser2210Pro mutation would abolish these
interactions and could thus alter conformation and/or stability of
LRBA. In contrast, with the variant p.R534W we identiﬁed in the B cell
receptor signalling protein SH3BP2, the side chain of Arg534 does not
interact with any residues within the SH2 domain (Fig. 5b). As Arg534
is exposed on the SH2 surface, the Arg534Trp mutation would
make SH3BP2 more hydrophobic and could therefore alter SH3BP2
interactions with its potential binding partners recognising the surface
of SH3BP2 centred on Arg534. The pR280W mutation of the
deubiquitinase TNFAIP3 (also known as A20) involves Arg280 which
Table 4
Overlap of enriched pathways betweenWGS and RNA-seq. Overview of the 24 pathways
found in both the 100 most signiﬁcantly enriched pathways for WGS and the pathways
signiﬁcantly enriched for differentially expressed genes from the RNA-seq analysis.
Pathway p value
RNA-seq
p value
WGS
Allograft rejection signalling 2.14E−03 4.74E−08
CD28 signalling in T helper cells 8.91E−03 1.01E−06
Haematopoiesis from pluripotent stem cells 1.82E−02 1.45E−06
Type I diabetes mellitus signalling 6.61E−03 3.90E−06
Graft-versus-host disease signalling 1.38E−02 7.66E−06
Autoimmune thyroid disease signalling 1.55E−04 8.86E−06
Dendritic cell maturation 2.69E−05 2.31E−05
Role of osteoblasts, osteoclasts and chondrocytes in
rheumatoid arthritis
2.95E−03 3.83E−05
Altered T cell and B cell signalling in rheumatoid arthritis 1.45E−02 5.36E−05
iCOS–iCOSL signalling in T helper cells 2.95E−02 5.61E−05
Communication between innate and adaptive immune cells 3.24E−03 5.88E−05
Systemic lupus erythematosus signalling 1.12E−02 6.39E−05
Role of NFAT in regulation of the immune response 5.89E−04 8.62E−05
T helper cell differentiation 9.33E−04 2.47E−04
PKCθ¸ signalling in T lymphocytes 8.91E−03 8.02E−04
IL-6 signalling 3.80E−02 8.83E−04
Role of macrophages, ﬁbroblasts and endothelial cells in
rheumatoid arthritis
1.91E−02 1.06E−03
IL-10 signalling 8.71E−04 1.31E−03
Tec kinase signalling 7.41E−03 1.89E−03
Type II diabetes mellitus signalling 3.80E−02 2.28E−03
Death receptor signalling 2.57E−02 3.78E−03
LPS-stimulated MAPK signalling 4.57E−02 4.84E−03
PEDF signalling 4.27E−02 1.34E−02
RANK signalling in osteoclasts 1.51E−02 1.80E−02
311P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314is locatedwithin the catalytic domain and stabilizes conformation of the
domain by binding to Asp279 (Fig. 5c) [70]. The Arg280Trp mutation
would abolish these interactions and thus might affect the overall con-
formation, catalytic activity and/or TNFAIP3–protein interactions. We
further assessed whether these three variants could affect protein sta-
bility using a programmemCSM [39]. All three mutations are predicted
to destabilize the proteins (change in Gibbs free energy, ΔΔG, kcal/mol:
LRBA Ser2210Pro, −0.236; SH3BP2 Arg534Trp, −0.461; TNFAIP3
Arg280Trp,−0.138).
4. Discussion
Here, we present the ﬁrst WGS analysis of sporadic CVID patients
and show that this does not reveal a unifying genetic aetiology in
terms of highly penetrant mutations involving a single gene or pathway
but rather that CVID is likely to include a number of different disease ae-
tiologies matching a polygenic model. We applied an analysis strategy
considering previously implicated candidate genes, loci implicated by
CVID GWAS, together with known primary immunodeﬁciency disorder
genes. Further investigation of genes with experimental evidence of
interaction with those involved in CVID-like antibody failure was infor-
mative. We adopted an integrated analysis that consideredWGS data in
the context of differentially expressed genes in CVID patients, allowing
interpretation in a biological context. We recognise that signiﬁcantly
larger sample sizeswould allow further progress in resolving the herita-
ble basis of CVID and resolving the current classiﬁcation of disease
aetiology. Our ﬁnding of a novel BTK mutation illustrates the diagnostic
power of the WGS approach.
Among the CVID patients analysed, we found variants in TNFRSF13B,
TNFRSF13C and NLRP12, consistent with previous ﬁndings [23–27]. We
also found a novel heterozygous variant in LRBA, which is predicted to
inﬂuence protein stability. Using our combined analysis strategy, we
are able to identify a number of important pathways where we ﬁnd
evidence of pathogenic mutations which together with biological evi-
dence that we and others have generated reveal likely signiﬁcantpathways in CVID. For example we found signiﬁcant enrichment in
WGS and differential gene expression analysis of ICOS–ICOS ligand sig-
nalling conﬁrming the previously found importance of this pathway in
antibody failure [10,11].
Other studies have previously shown that deﬁciency in genes
involved in B-cell receptor sequencing (CD19, CD21, CD81, PLCG2,
PI3KCD) can lead to CVID-like antibody deﬁciencies [4–8,15,16]. In our
analysis we found heterozygous coding variants in a variety of genes in-
volved in this pathway (IKBKB, CD79a, BTK, KRAS, ARID3A, INPP5D,
BANK1, BLK, and GAB2) including a number of novel variants in BTK,
BLK and ARID3A. In one patient we found reduced expression and two
variants (one coding and one non-coding) in SH3BP2. The coding
variant might alter interactions with potential binding partners.
Moreover, in our RNA-seq analysis BCR signalling was one of the most
signiﬁcantly enriched pathways in CVID patients.
Previous studies showed that variants in BAFF-R, a receptor impor-
tant for B-cell survival, can cause or predispose to CVID [12,27,44].
We, and others, show increased expression of FAS, an apoptosis induc-
ing receptor, in CVID patients [66]. Moreover, we found a variant
whichmight alter the overall conformation of TNFAIP3, a gene inhibiting
TNFα induced apoptosis, and novel variants in TNIP1which is a known
TNFAIP3 interaction partner. Death receptor signallingwas signiﬁcant in
pathway analysis of both the RNA-seq andWGS analyses together sug-
gesting that apoptosis might be dysregulated in a subgroup of CVID
patients.
As NHEJ is essential in V(D)J recombination and class–switch recom-
bination, inefﬁcient NHEJ could lead to CVID like symptoms. We ﬁnd
variants in DCLRE1C, PRKDC, RAG2, NHEJ1, MRE11A, ATM and NLRP2 in
our patients, all genes important in the initiation of V(D)J recombina-
tion or DSB repair by NHEJ. The hypothesis that NHEJ defects could
lead to CVID in a subgroup of patients is supported by the recent ﬁnding
of a leaky block in B-cell development in a study comparing the bone
marrow of CVID patients and healthy controls [71].
Our analysis also highlighted the role of T-cells in sporadic, non fa-
milial CVID. We found variants in genes associated with T-cell regula-
tion (IL21R, STIM1, TAP2) with WGS. Pathway analysis of both the
RNA-seq andWGS data revealed enrichment of a number of T-cell relat-
ed pathways (T helper cell differentiation; CD28 signalling; ICOS–ICOSL
signalling). Dysregulation of T cells could also be the result of pathways
found to be signiﬁcantly enriched in the WGS data related to dendritic
cell maturation, interaction between innate and adaptive immune
cells and cytokine signalling (IL-18, IL6 and IL10) which would lead to
B cell dysfunction through altered B–T cell interactions in CVID patients.
Interestingly, we found a relatively high number of T-cell related
pathways in our RNA-seq analysis, having investigated and compared
the expression proﬁles of samples enriched for B-cells. One possible ex-
planation is the presence of residual T-cells in our samples (61.9–96.1%
B-cell purity). Alternatively, genes that are important in T-cell signalling
pathways could also be expressed in B-cells and therefore be found in
our analysis.
In oneof our CVIDpatientswe identiﬁed variants in the 3′UTR region
of two genes involved in IL-7R signalling (BCL2L11 and EBF1) [63,64]. 3′
UTRs are important for the determination of translation efﬁciency, local-
ization and stability ofmRNA. Inmice IL-7R signalling and EBF-1 expres-
sion have been described as central regulators in B cell development
where their interplay positively regulates B lineage commitment,
survival and proliferation [64]. In humans, EBF-1 is important in B-cell
lineage commitment [63]. In contrast, the role of IL-7R signalling in
B-cell development seems less important as patients with IL-7Rα deﬁ-
ciency have normal B-cell numbers.
Together our data illustrate the strength of a combined approach
using WGS and RNA-seq and highlight that CVID is a highly heteroge-
neous and polygenic disease. Our results corroborate with previous
ﬁndings in TNFRSF13B, TNFRSF13C and NLRP12. Moreover, our data
highlight variants in genes involved in ICOS–ICOSL signalling, regulation
of apoptosis, and BCR signalling. We were also able to identify novel
ab
c
Fig. 5.Mapping of predicted deleterious variants onto protein structures and linking proteins of interest to CVID. Proteins are shown as ribbon diagrams and coloured in blue-to-red
transitions (N-termini, blue; C-termini, red). Side chains of selected variants are shown as connected spheres (oxygen, red; nitrogen, blue) and are circled in the panels on the left.
Zoom-in views are presented in the panels on the middle with side chains shown as sticks. Distances between selected atoms are indicated with dashed lines. The right panel shows
how these proteins could be linked to CVID. (a) The crystal structure of the C-terminal fragment of human LRBA encompassing the pleckstrin homology (PH, blue) and the beige and
Chediak–Higashi syndrome (BEACH, green-to-red) domains (PDB code 1T77) [69]. The side chain of Ser2210 makes hydrogen bonds to Glu2213 (both main chain and side chain) and
the side chain of Arg2397. Amino acid numbering corresponds to UniProt entry P50851, isoform 2. (b) Solution NMR structure of the SH2 domain of SH3BP2 (PDB 2CR4; UniProt
P78314, isoform 4). The side chain of Arg534 is exposed on the protein surface and does not make any bonds with other residues. (c) The crystal structure of the catalytic domain of
TNFAIP3 (PDB 3ZJE; UniProt P21580) [70]. The side chain of Arg280 is exposed on the surface and makes hydrogen bonds to the side chain of Asp279.
312 P.A. van Schouwenburg et al. / Clinical Immunology 160 (2015) 301–314pathways which may be important for CVID, including NHEJ, T cell reg-
ulation and cytokine signalling. However, functional follow-up studies
in individual patients are needed to conﬁrm the role of variable path-
ways involved in the pathogenesis in CVIDs.Acknowledgements
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